Pulse Biosciences (NASDAQ:PLSE) Shares Down 1.4% – Should You Sell?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) dropped 1.4% during mid-day trading on Thursday . The stock traded as low as $14.02 and last traded at $14.10. Approximately 218,228 shares traded hands during mid-day trading, an increase of 34% from the average daily volume of 162,256 shares. The stock had previously closed at $14.30.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $22.00.

Pulse Biosciences Trading Up 1.1%

The firm has a 50 day moving average price of $14.07 and a 200 day moving average price of $15.56. The stock has a market capitalization of $965.72 million, a PE ratio of -12.61 and a beta of 1.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the last quarter. Alliancebernstein L.P. grew its stake in Pulse Biosciences by 6.7% during the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after acquiring an additional 1,300 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Pulse Biosciences by 44.0% during the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after acquiring an additional 1,372 shares in the last quarter. Rhumbline Advisers grew its stake in Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company’s stock valued at $440,000 after acquiring an additional 1,614 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after acquiring an additional 2,156 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.